Acceleron resurrects blockbuster hopes for sotatercept with positive PhII — and shares rocket up
Acceleron $XLRN says that its first major trial readout of 2020 is a success.
In a Phase II study of 106 patients with pulmonary arterial …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
